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Abstract
Introduction: Schizophrenia is an important cause of disability and consumption of economic resources. This study 
aims to estimate the costs and the burden of schizophrenia in mainland Portugal in 2015.
Methods: The burden of disease was measured through disability-adjusted life years (DALY), a metric adopted by the 
World Health Organisation. The cost of illness was estimated based on the prevalence and adopting a comprehensive 
perspective of society. Costs included direct consumption of resources and indirect costs of patients and caregivers 
(loss of productivity). The main sources of cost data were: Diagnosis Related Groups (DRG), healthcare delivery contracts, 
drug consumption, and expert opinion.
Results: The prevalence of schizophrenia is approximately 48,000 patients, and approximately 41,000 patients are fol-
lowed in the healthcare system (both public and private units). In 2015, 28,588 DALYs were lost (84% due to disability; 
16% due to premature death). At 2015 prices, estimated direct costs totalled €96.1 million, while indirect costs totalled 
€340.3 million; 97% of the indirect costs were generated by patients, the remaining by the caregivers. 
Conclusion: Schizophrenia has an important social impact in Portugal due to the associated morbidity, with a total esti-
mated cost in 2015 of €436.3 million, approximately 0.24% of the Gross Domestic Product. Direct costs represent 0.6% of 
all healthcare expenditures during 2015, while total costs (direct and indirect) represent 2.7% of healthcare expenditures.
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Introduction
Schizophrenia is a chronic, clinically diagnosed disease 
that presents at young age. Despite the heterogeneous 
course of disease, the evolution of schizophrenia is de-
scribed as favourable in about 20% of individuals and com-
plete recovery is rare. Most patients remain chronically 
ill, with exacerbations and remissions of active symptoms, 
while others have a course of progressive deterioration 
[1]. Schizophrenia has a significant impact on different 
domains of human life, namely those related to work, ed-
ucation, interpersonal relationships, ability to live inde-
pendently, and self-care [2].
Cost of illness studies aim to measure and evaluate the 
impact of a disease in terms of consumption of economic 
resources, as well as the impact on economic activity gen-
erated by the associated disability [3]. On the other hand, 
disease burden studies aim to quantify, in a general index, 
the effects of illness on the health level of a given popula-
tion [4]. Together, these studies aim to establish a rigorous 
picture of a given health condition and its magnitude, thus 
contributing to the definition of priority areas that may 
need resources, and to establish research and intervention 
plans within healthcare systems.
Schizophrenia was ranked as the 11th most important 
cause of disease burden globally in 2015 when measured by 
total years of disability [5]. According to studies conducted 
in other countries, schizophrenia is also associated with di-
rect costs (including consumption of healthcare resources) 
and indirect costs (generated, for example, by the loss of la-
bour productivity) that have relevant societal impact [6, 7].
Despite this international recognition that schizophre-
nia is an important cause of disability and is characterised 
by high consumption of economic resources, detailed and 
updated data for the Portuguese population are not avail-
able. In this context, this study aims to estimate the cost 
and burden of schizophrenia in mainland Portugal in 2015.
Methods
The burden of disease was estimated through disabili-
ty-adjusted life years (DALY), a metric introduced by the 
World Bank and the World Health Organisation (WHO), 
which has now been used in disease burden studies con-
ducted since 1990 [8]. This methodology uses epidemio-
logical data, in particular the incidence of the disease by 
severity stages, the duration of each stage, and the patient 
mortality patterns.
The cost of illness was estimated based on the preva-
lence and adopting a comprehensive perspective of society 
(not only the perspectives of patients, healthcare systems, 
hospitals, etc.) [9]. This method considers the number of 
patients with schizophrenia in the year of analysis and their 
annual direct and indirect costs associated with the disease.
It should be noted that this type of study uses a wide 
variety of data sources, both in the types of sources and in 
the period of reference. In the absence of national data, ep-
idemiological parameters retrieved from the international 
scientific literature are used. In this context, to estimate the 
cost and burden of schizophrenia, it was necessary, in the 
first phase, to obtain estimates of the prevalence, incidence, 
and mortality of schizophrenia in mainland Portugal.
Estimates of prevalence, incidence, and mortality of 
schizophrenia in mainland Portugal
According to a recent systematic review that included 65 
observational studies, the median lifetime prevalence of 
schizophrenia in the European general population was 
estimated at 0.52% (IQR: 0.39–0.87%). Estimates were, 
nonetheless, heterogeneous between studies (variation: 
0.21% to 1.3%) [10]. In Portugal, there are no studies on 
the prevalence of schizophrenia. Therefore, to estimate the 
prevalence in Portugal, we used data on the consumption 
of antipsychotics.
First, the number of patients receiving antipsychotic 
drugs was estimated based on official drug consumption 
data from the outpatient clinic of the Regional Health 
Administration of Lisbon and Tagus Valley (ARSLVT) 
(which includes a population of over 3.6 million individ-
uals) and sales data provided by IMS Health (2016). Drug 
consumption in terms of packages was converted into the 
number of patients under treatment considering the daily 
defined dose (DDD) of each active ingredient. In the case 
of antipsychotic drugs with approved therapeutic indica-
tions beyond schizophrenia, the proportion of sales attrib-
utable to schizophrenia was estimated. This proportion 
was calculated using the distribution of pathology groups 
as reported in the 3rd Portuguese Psychiatric Census [11]. 
It was also considered that a proportion of patients is un-
der treatment with more than one antipsychotic drug. 
The proportion of patients on concomitant injectable 
and oral therapy and the proportion of patients on two 
concomitant oral therapies were estimated on the basis of 
expert opinion at 35% and 50%, respectively. Secondly, it 
was necessary to assume that, at any moment, only a pro-
portion of patients adhere to antipsychotic therapy. Based 
on expert opinion, an average rate of adherence of 75% 
was considered. Finally, to estimate the prevalence rates 
of schizophrenia by gender and age group in mainland 
Portugal in 2015, the results of the 3rd Psychiatric Census 
[11] were considered.
Regard mortality due to schizophrenia, in 2014, the 
disease was identified as the cause of death in only 14 
deaths reports in Portugal [12]. For the 2010-2014 period, 
the average annual number of deaths due to schizophrenia 
is less than 18. However, there is solid evidence that pa-
tients with schizophrenia have an increased mortality risk 
compared to the general population, with a standardised 
mortality ratio of 2.50 (95% CI: 2.18 to 2.43), as estimated 
in the systematic review by Saha et al. (2007) [13]. These 
two outcomes (near-zero schizophrenia mortality and 
increased mortality risk) are, however, compatible since 
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deaths in patients with schizophrenia can be attributed to 
causes other than schizophrenia per se (e.g. self-inflicted le-
sions, unintentional, infectious diseases, substance abuse, 
cardiovascular disease, and neoplasms) [14].
According to an overview of three systematic reviews 
of the literature on the incidence, prevalence, and mortal-
ity associated with schizophrenia, including 158 studies 
in 32 countries, the overall incidence of schizophrenia in 
2008 was estimated at 15.2/100,000 individuals, but there 
is a significant variability between studies and countries 
(interquartile range [IQR]: 10.2 to 22.0/100.000 individ-
uals) [15]. As with prevalence, no data are available on the 
incidence of schizophrenia in Portugal.
To estimate the incidence and duration of the disease in 
Portugal, the DISMOD II model was used, which is a tool 
developed by the WHO [16]. This model ensures internal 
consistency between epidemiological parameters of the dis-
ease: incidence rates, prevalence, remission, lethality, mor-
tality or relative risk (RR) of mortality, and durations. The 
model requires a minimum of three inputs, which in this 
case were the prevalence (estimated by the authors using the 
described methodology), the relative risk of death (as esti-
mated by Saha et al.) [13], and the remission of the disease 
(here defined as cure of the disease and assumed to be zero 
as there are no curative treatments for the disease) [17].
Burden of disease
The burden of disease was estimated through DALYs, a 
measure, expressed in time, of the amount of health lost due 
to disability generated by the disease or premature death. It 
includes two components: 1) years of life lost (YLL) due to 
premature death, with time lost estimated as the difference 
between age at death and standard life expectancy for that 
age; and  2) Years lost due to disability (YLD), which con-
siders time spent suffering from disability [4].
Standard life expectancy was obtained from the mor-
tality tables adopted as standard of reference [4]. Disabil-
ity was measured by a coefficient with scores between 0 
(without any disability, perfect health) and 1 (total disabil-
ity or death). To estimate the number of DALYs lost by an 
individual, the following equation was used:
where:
In the calculation of the DALYs, a discount rate of 3% 
and an age-differentiated weighting were used, in which 
intermediate age groups (between 20 and 50 were given 
more weight than the younger and older groups) [4] (Fig-
ure 1, supplementary material). It was considered that all 
prevalent patients, even without diagnosis, and therefore 
without follow-up, contribute to the burden associated 
with the disease.
Years of life lost (YLL) due to premature death
As mentioned previously, deaths due to schizophrenia in 
Portugal [12] are not the most adequate source to estimate 
YLLs due to schizophrenia. In this context, YLLs were es-
timated considering that a fraction of the overall mortality 
in patients with schizophrenia may be attributable to the 
disease. In this case, following the approach that uses the 
concept of attributable fraction [19], the fraction of total 
mortality attributable to schizophrenia was determined by 
the equation:
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 = & 𝐷𝐷𝐷𝐷𝐷𝐷𝑒𝑒*+,𝑒𝑒*-(,*/)𝑑𝑑𝐷𝐷
/23
/
where RR is the relative risk of death in patients with 
schizophrenia. The RR of mortality in schizophrenia con-
sidered was estimated by Saha et al. (2007) (2.50) [13], 
whereby the attributable fraction is 60%.
The number of deaths, by sex and age group, to which 
the fraction attributable to schizophrenia was later applied, 
was estimated from the DISMOD II model, in accordance 
with the previously described calibration assumptions.
Years lost due to disability (YLD)
To estimate YLDs, the methodology and disability weights 
applied in the Global Burden of Disease 2015 study [5] 
were used. For schizophrenia, this study considers two 
stages, acute and residual, whose disability weights were 
estimated at 0.778 and 0.588, respectively.
To apply these disability weights, the overall incidence 
of schizophrenia needs to be distributed for each of the 
stages, which was done in the Global Burden of Disease 
2015 study based on the results of the systematic review by 
Ferrari et al. (2012) [20]. The parameters used are summa-
rised in Table 1.
Given the lack of more detailed information in the lit-
erature, it was considered that the distribution of incident 
cases for the two stages (according to Table 1) was inde-
pendent of the age of onset and duration of the disease.
Cost of illness
Cost of illness was estimated from the prevalence per-
spective. Conservatively, it was assumed that only fol-
low-up patients generate costs. Direct costs (healthcare 
consumption of the patients themselves) and indirect 
costs (productivity losses of patients and caregivers) were 
considered. 
a - initial age.
L - length of disability or years of life lost due to premature 
death.
D - coefficient of disability, between 0 e 1.
C - constant - correction for age (0.04).
X - age, varies between a and a+L.
β - parameter from the rule for age correction (0.1658) [18].
r - rate of time discount (3%).
Attributable Fraction=(RR-1)/RR
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Direct costs
The direct costs considered were: 1) hospitalisation, am-
bulatory hospital visits, and others; 2) emergency depart-
ment visits without hospitalisation; 3) outpatient visits of 
psychiatry, mental health, and general and family medicine 
(GFM); 4) pharmacological therapy; and 5) transport.
Costs of hospitalisation, ambulatory hospital visits, and others 
Consumption of resources for hospitalisations and ambu-
latory hospital visits was assessed using the Diagnosis Re-
lated Groups (DRG) database of the 2015 National Health 
Servicei. In the DRG database, episodes of patients over 
the age of 15 and with the main diagnosis of schizophrenia 
(International Classification of Diseases 9, Clinical Modi-
fication, ICD 9-CM equals 295.XX)ii were identified. The 
unit cost of hospitalisation episodes was estimated based 
on the prices of Ordinance No. 234/2015 of August 7 
(https://dre.pt/application/file/a/69965783, accessed in 
July 2017), which approves the regulation and the price 
lists of institutions and services integrated in the national 
health service.
Resource consumption, and their respective costs, gen-
erated in the context of the hospitalisation of chronic pa-
tients, rehabilitation, ambulatory hospital, and home psy-
chiatry visits was estimated using a top-down methodology 
[21]. Initially, the overall costs associated with psychiatric 
patients was estimated and, then, the proportion of these 
costs specifically associated with schizophrenia patients was 
estimated. The overall psychiatry costs were estimated based 
on the prices and consumptions reported in the 2015 health-
care delivery contracts (signed between national health ser-
vice hospitals and entities that represent the national health 
service) and the 2015 "Reports and Accounts" documents of 
each psychiatric hospital ( Hospital Magalhães Lemos, EPE 
and Psychiatric Hospital Center of Lisbon) (Table 2).
The proportion of consumption presented in Table 2 
that is specifically attributable to schizophrenia patients 
was estimated based on the results of a panel of 3 experts 
(Delphi methodology) with national representativeness.
Costs of emergency department visits
The use of the emergency department (without subse-
quent hospitalisation) was estimated based on the results 
of the panel of experts and by searching the DRG database. 
According to expert opinion, on average, 70% of patients 
who go to the emergency department of psychiatry due to 
schizophrenia are not hospitalised. The number of emer-
gency visits without hospitalisation was estimated based 
on this proportion as well as the number of hospitalisation 
episodes due to schizophrenia with urgent admission (by 
consulting the DRG database).
The unit cost of emergencies without hospitalisation 
was calculated as the weighted average of the prices of 
hospital emergency department visits reported in health-
care delivery contracts of the national health services 
hospitals. The weighting was performed according to the 
distribution of the number of hospitalisation episodes 
for schizophrenia with urgent admission in the national 
health service hospitals.
Costs of ambulatory hospital visits
Consumption of ambulatory psychiatric and mental health 
visits in the community was estimated from the total 
number of visits reported in the annual report on access 
to healthcare in the national health service and contract-
ed entities in 2014, and in healthcare delivery contracts, 
respectively. The proportion of visits attributable to schiz-
ophrenia (12.4%) was estimated based on the results of the 
3rd Psychiatric Census [11]. Ambulatory psychiatric visits 
in the public sector were increased by 28.8% to include the 
contribution of the private sector; according to the pro-
portion of antipsychotics with exclusive therapeutic indi-
cation for the treatment of schizophrenia prescribed in the 
private sector. Based on the number of ambulatory visits of 
psychiatry and considering an average of three follow-up 
visits per patient per year (expert opinion), it was possi-
ble to estimate the number of patients in follow-up (in the 
public and private sector).
The unit cost of psychiatric and mental health visits 
in the community was estimated through the healthcare 
delivery contracts of national health service hospitals for 
2015, assuming that this amount already includes the ex-
iSource: Administração Central do Sistema de Saúde ACSS, I.P.
iiIt should be noted that, in the case of schizophrenia, there is a substantial pro-
portion of long-term hospitalisations, that is, beyond the maximum duration 
threshold contemplated in the DRG. In these cases, costing rules were applied 
evaluating the days in excess of the daily rate indicated in the legislation.
Table 1. Disability weighting factors and distribution  by schizo-
phrenia stages.






Hears and sees 
things that are not 
real and is afraid, 
confused, and 
sometimes vio-
lent. Has difficulty 
in communication 
and activities of 
daily living and 
sometimes wants 






Hears and sees 
things that are not 
real and has com-
munication prob-
lems. May have 
forgetfulness, has 
difficulties in activ-
ities of daily living, 




95% CI: 95% confidence interval. 
Source: Adaptated from GBD 2015 Disease and Injury Incidence and Prev-
alence Collaborators (2016) [5] e de Ferrari et al. (2012) [20]. 
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Table 2. Estimate of resource consumption and respective price for psychiatric patients in national health service hospitals.
Psychiatric Hospitalsa Other Hospitals
No days / 
sessions
Value (€) Unit cost No days / 
sessions
Value (€) Unit cost
Hospitalisation of chronic patients 
Hospital 71,038 5,025,939 70.75 65.554 2,597,023 39.62
External (religious orders) 294,491 11,535,212 39.17 607.601 23,785,107 39.15
External (other institutions) 58,321 2,282,014 39.13 49.331 1,932,295 39.17
Psychosocial Rehabilitation 48,374 3,422,461 70.75 2.500 176,875 70.75
Ambulatory hospital
Psychiatry 54,620 1,665,364 30.49 133.367 4,085,512 30.63
Psychology – socio-occupational 26,904 820,303 30.49 11.840 361,002 30.49
Rehabilitation structuresb
Psychiatry 31,312 954,703 30.49 - - -
Home visits (Psychiatry)
Psychiatry 9,035 299,059 33.1 - - -
aHospital de Magalhães Lemos, E.P.E. e o Centro Hospitalar Psiquiátrico de Lisboa.
bThis section is only completed in the healthcare delivery contract for Hospital de Magalhães Lemos, E.P.E., thus the number of sessions corresponds 
only to the production of this hospital.
Source: healthcare delivery contracts of national health service hospitals e “Report and Accounts” documents of Hospital de Magalhães Lemos, E.P.E. 
and Centro Hospitalar Psiquiátrico de Lisboa.
penses with the visits itself and with the possible use of 
complementary means of diagnosis.
To estimate the number of GFM visits, the proportion 
of psychiatric visits with primary care referral reported in 
the healthcare delivery contracts (9.6%) was considered 
and it was assumed that, for each patient referred, two 
GFM visits would occur.
The unit cost of the consultation considered was 
€31.00, according to the price defined in Ordinance No. 
234/2015 of August 7.
Costs of pharmacological therapy
To estimate the cost of antipsychotic pharmacological ther-
apy in the ambulatory setting,  the same sources and as-
sumptions used to estimate the prevalence of patients with 
schizophrenia in Portugal were applied. In addition, the 
cost of other pharmacological therapies with action on the 
central nervous system (Anatomical Therapeutic Chemical 
[22] codes N05B, N05C, N044AA01 N04AA02 N06A and 
N03) were also considered. These ATC classes were select-
ed based on the national study by Simões do Couto et al. 
(2011) [23] in which the demographic and clinical charac-
teristics of 474 patients with schizophrenia were monitored 
between 2004 and 2005. The proportion of non-institu-
tionalised patients treated with each class was estimated 
by the panel of experts. Unit prices for non-antipsychotic 
drugs with central nervous system action result from the 
weighted average prices per mg (http://app7.infarmed.pt/
infomed/inicio.php, Infomed - IINFARMED, IP, accessed 
in June 2017) and market shares (IMS Health 2012). The 
annual price was calculated based on the DDD (https://
www.whocc.no/atc_ddd_index/, accessed July 2017).
Costs of transport
Direct costs also included travel costs associated with ur-
gent transport (to travel to the emergency department) and 
non-urgent transport (to travel to visits). The details of the 
estimated transport costs are presented in supplementary 
material (Table 1, supplementary material).
Indirect costs
Indirect costs included the costs of patients and their car-
egivers of working age, that is, under 65 years of age.
Patient costs
Patients were distributed in four mutually exclusive 
groups: 1) those who work with an unprotected job; 2) 
those who have protected jobs [24]; 3) those who would 
work if they did not have the disease; and 4) those who 
would be unemployed even if they did not have the dis-
ease. Groups 1 and 2 generate absenteeism costs. Group 
2 generates costs associated with lost production by re-
duced productivity of patients with schizophrenia. Group 
3 generates costs associated with lost production due to 
the disease because of non-participation in the labour 
market. The last group does not generate indirect costs.
To estimate the average productivity of workers, the 
Human Capital theory [25] was adopted. According to 
this theory, indirect costs—measuring the lost produc-
tion due to the disease—are estimated based on the costs 
for employees incurred by the employer. The informa-
tion considered to estimate indirect costs is summarised 
in Table 3.
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Caregivers costs
Based on expert opinion, it was estimated that 14.9% of pa-
tients in follow-up have an employed caregiver. The annual 
cost per caregiver in Portugal was estimated based on the 
results of the study by Gupta et al. (2015) [26]. This study 
estimates the annual indirect costs of caregivers of patients 
with schizophrenia, compared to non-caregivers, using the 
results of national health surveys from 5 European coun-
tries (EU5). The difference in annual indirect costs between 
the two groups (€ 2,872) was adjusted by the ratio (53%) 
between Portuguese GDP and the EU5 weighted average of 
GDP [27] to reflect lower productivity in Portugal.
Ethical responsibilities
This research did not use human participants and no pa-




The number of patients receiving antipsychotic drugs in 
mainland Portugal during 2015 was estimated at 36,032 
based on drug consumption data. When applying a 75% ad-
herence rate, the number of prevalent patients was estimat-
ed at 48,042, corresponding to a crude prevalence rate in the 
population >15 years old of 0.57%. This estimate is in line 
with the results of the systematic review by Simeone et al. 
(2015) [10] (0.52% in the European population in general).
Years of life lost (YLL) due to premature death
The distribution of deaths from all causes and for schizo-
phrenia, by age groups and gender, is presented in supple-
mentary material (Table 2, supplementary material). The 
total number of deaths attributable to schizophrenia dur-
ing 2015 was 223 in men and 180 in women, respectively, 
which in aggregate corresponds to 0.39% of overall mor-
tality. Based on these results and the standard life expec-
tancy, we estimated that in Continental Portugal in 2015, 
there were 4,041 YLLs lost due to schizophrenia (62% in 
men), which corresponds to 0.81% of total YLLs lost due 
to overall mortality.
Figure 1 shows the distribution of YLLs due to schiz-
ophrenia, by gender and age groups. The distribution by 
age group is slightly different between genders. The loss 
of YLLs is greater between 55 and 59 years in men and 
between 65 and 69 years in women.
Years lost due to disability (YLD)
Epidemiological data estimated in DISMOD II and used in 
the calculation of YLDs are summarised in Figure 2 and sup-
plementary material (Table 3, supplementary material).
Based on these data and considering the disability 
weights and distribution among severity stages (Table 1), 
we estimated 24,547 YLDs due to schizophrenia in main-
land Portugal in 2015, 62% of which in men.
Figure 3 shows the distribution of YLDs due to schiz-
ophrenia, by gender and age groups. Most of the burden 
(74%) falls in the age groups between 15 and 34 years. 
These age groups present the highest disability weights 
(Figure 1, supplementary material) and the highest inci-
dence rate of schizophrenia (Figure 2).
Disability-adjusted life years (DALY)
The sum of YLLs and YLDs results in a total burden of 
schizophrenia of 28,588 DALYs in 2015 (Table 4).
Table 3. Information considered to estimate the indirect costs associated with schizophrenia patients.
No Information Estimate Source
1 No of patients in follow-up under 65 years of age 32,568 Authors estimate
2 Proportion of patients with unprotected job 10.35% Expert panel
3 Proportion of patients with protected job 4.65% Expert panel
4 Proportion of patients that are not involved in the 
labour market
85.0% Calculated from inputs no 2 and 3
5 Rate of employment of the overall populationa 67.7% Rate of employment in the 4th trimester of 2015 (INE 2016)
6 Ratio of the productivity of patients with protected job 
vs. the overall population
80.0% Ratio of the average salary of patients with disability com-
pared to the overall population (OECD) 2009
7 Daily income per workerb per work day 87.99€ Employment statistics from March 2016 referring to April 
2015 and authors estimates
8 Annual income per workerb 20,238.82€ Employment statistics from March 2016 referring to April 
2015 and authors estimates
9 No of work days lost per consultation 0.5 Assumption
10 No of work days lost per emergency episode (without 
hospitalisation)c
1 Assumption
INE – National Statistics Institute; OECD - Organisation for Economic Co-operation and Development.
aGeneral population with the same distribution of schizophrenia patients by age group and gender.
bUsing a gender distribution similar to that of schizophrenia patients.
cTravel to the emergency department due to schizophrenia during working hours estimated at 50% of total.
7Gouveia et al.
International Journal of Clinical Neurosciences and Mental Health 2017; 4(Suppl. 3):S13
Direct, indirect, and total costs
In the 2015 DRG database, there were 3,124 inpatient 
episodes with the main diagnosis of schizophrenia, cor-
responding to the hospitalisation of 2,429 patients. 
Most of the episodes (92%) corresponded to emergency 
admissions. The average price per episode was estimat-
ed at €3,722.5. The total cost related to hospitalisation 
episodes was estimated at €11,629,215. There were no 
ambulatory episodes in the DRG database with the main 
diagnosis of schizophrenia.
Table 5 summarises the consumptions, unit prices, 
and estimated total costs of the remaining sources of di-
rect costs considered in the analysis. The calculation of 
costs with pharmacological therapy (antipsychotic and 
other) is summarised in the supplementary material (Ta-
ble 4, supplementary material). The total direct cost as-
sociated with schizophrenia in mainland Portugal in 2015 
was €96,075,590.
Indirect costs generated by patients and caregivers to-
talled €340,273,639 (Table 5). The vast majority of indi-
rect costs (95%) are associated with non-participation of 
patients in the labour market.
The overall costs attributable to schizophrenia in 2015 
in mainland Portugal totalled €436,349,229, 78% of which 
are indirect.
Discussion
Schizophrenia, as other areas of mental health, is a poorly 
captured in health information systems. This problem is 
particularly striking in Portugal, where any research of an 
epidemiological or economic nature encounters enormous 
obstacles due to the difficulties in accessing the necessary 
data, and in some cases, due to lack of such data. 
During the execution of this study, we found an sub-
stantial lack of epidemiological data for the Portuguese 
population, with no information on the prevalence, inci-
dence, or even mortality patterns of patients with schizo-
phrenia. The lack of epidemiological data is exacerbated by 
the lack of data on resource consumption beyond what is 
listed in the DRG database. These problems are worsened 
by the specificities of the care provided to these patients, 
including long-term hospitalisations, use of providers in 
the social system, etc. Finally, data on indirect costs, both 
for patients and caregivers, is scarce or non-existent, in-
cluding studies on the effects of early exit from the labour 
market on caregivers' lives.
 Despite these difficulties, or perhaps because of them, 
schizophrenia is an area where improvements in knowl-
edge can be extremely relevant to better manage the health-
care system, and to improve policies and optimise the use 
of resources. For example, the recent effort of Perelman 
et al. (2017) [28] containing proposals for improving the 
model of mental health care financing in Portugal.
The study of the costs and burden of disease in a pa-
thology with a human dimension as relevant as schizo-
phrenia has a high potential to leverage improvements in 
the health of a group of Portuguese people deserving our 
full attention.
The present work attempted to overcome the above 
mentioned problems by relying mostly on what we can call 
indirect estimation techniques. Thus, the few but precious 
epidemiological data were complemented with epidemio-
logical information inferred from the patterns of drug con-
sumption. In some cases, information on studies in other 
countries was used to obtain estimates of variables in the 
Portuguese context. We needed to make use of hospital 
Figure 1. Years of life lost (YLL) due to premature death attributable to schizophrenia in mainland Portugal, by age groups and 
gender, 2015.
Cost and burden of schizophrenia in Portugal8
ARC Publishing
Figure 2. Incidence (A) and estimated duration (B) of schizophrenia in mainland Portugal, 2015.
A
B
contract data to fill many statistical gaps, a strategy that 
is not usually required in the cost and burden studies of 
other pathologies. In many cases, the informed opinion of 
experts was the only available information. Although the 
use of several estimates may be fragile and inaccurate, we 
believe that the aggregate quantities estimated in this work 
are reliable estimates of the amounts involved.
The final results show that there should be almost 
50,000 patients with schizophrenia in Portugal and that of 
these more than 40,000 are being followed in the health-
care system.
Regarding the burden of disease in  2015, it is estimat-
ed that 24,547 years of life have been lost due to disability 
attributable to schizophrenia. As for the burden generated 
by mortality, 403 deaths were attributed to schizophrenia, 
resulting in a total of 4,041 years lost due to premature 
death. When comparing mortality and YLLs generated 
by schizophrenia with mortality and YLLs from all causes, 
YLLs for schizophrenia correspond to 0.81% of total YLL 
for overall mortality. This percentage is more than double 
the percentage of deaths due to schizophrenia (compared 
to total deaths), which can be explained by the fact that 
9Gouveia et al.
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Figura 3. Years lost due to disability (YLD) attributable to schizophrenia in mainland Portugal, 2015.
Table 4. Disability-adjusted life years (DALY) attributable to 
schizophrenia in mainland Portugal, 2015.
YLL YLD DALY 
Men 2,511 15,215 17,726
Women 1,531 9,332 10,863
Total 4,041 24,547 28,588
YLL - Years of Life Lost; YLD - Years Lost due to Disability
deaths in schizophrenia occur, on average, at an earlier age 
than overall deaths.
Overall, the burden of schizophrenia was estimated at 
28,588 DALYs. As might be expected, although the disease 
burden due to premature death is not zero, the burden due 
to disability is the most relevant, accounting for 86% of the 
total DALYs.
Regarding the cost of disease in 2015 prices, the esti-
mated total direct cost associated with schizophrenia was 
€96.1 million. To these direct cost we have to add the indi-
rect cost generated by the patients (absenteeism, non-par-
ticipation in the labour market, reduced productivity), 
and by caregivers, respectively, €331.0 million and €9.3 
million. This result is very different from what is usually 
estimated for other diseases, since indirect costs account 
for 78% of total cost. In other diseases, indirect costs are 
almost always a minority of total cost [29-32].
The total cost of schizophrenia was estimated at €436.3 
million, approximately 0.24% of GDP in 2015. Direct costs 
account for 0.6% of all healthcare expenditure in 2015, 
while total costs (direct and indirect) represent 2.7% of 
healthcare expenditure. 
Another recent study used similar methodologies to 
evaluate the cost and burden of atrial fibrillation in Por-
tugal [30]. The costs and burden associated with schizo-
phrenia are approximately 3.1 and 1.23 times higher than 
atrial fibrillation, respectively. Despite the limitations of 
this type of indirect comparisons, the results of the pres-
ent study document the high socio-economic impact that 
schizophrenia has in Portugal and at the same time indicate 
that schizophrenia is an area where significant health gains 
can be obtained. Therefore, schizophrenia should be a pri-
ority area for the healthcare system.
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